Celldex Therapeutics CLDX Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Celldex Therapeutics’s reported figures.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's free cash flow?
- Celldex Therapeutics (CLDX) reported free cash flow of -$67.23M in Q1 2026.
- How has Celldex Therapeutics's free cash flow changed year-over-year?
- Celldex Therapeutics's free cash flow decreased by 23.0% year-over-year, from -$54.64M to -$67.23M.
- What is the long-term trend for Celldex Therapeutics's free cash flow?
- Over 4 years (2021 to 2025), Celldex Therapeutics's free cash flow has grown at a 36.2% compound annual growth rate (CAGR), from -$62.16M to -$213.66M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.